Barry Moze - Jul 8, 2021 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co (HZNP)

Role
EVP, Chief Admin. Officer
Signature
/s/ Miles W. McHugh, Attorney-in-Fact
Stock symbol
HZNP
Transactions as of
Jul 8, 2021
Transactions value $
-$3,246,012
Form type
4
Date filed
7/9/2021, 05:00 PM
Next filing
Jul 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Sale -$740K -8.1K -7.59% $91.35 98.6K Jul 8, 2021 Direct F1, F2, F3
transaction HZNP Ordinary Shares Sale -$1.14M -12.4K -12.52% $92.64 86.3K Jul 8, 2021 Direct F1, F4
transaction HZNP Ordinary Shares Sale -$1.36M -14.6K -16.95% $93.12 71.6K Jul 8, 2021 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.86 to $91.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Includes 1,050 ordinary shares of the Issuer acquired by the reporting person on June 1, 2021 pursuant to an employee stock purchase program.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.92 to $92.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.92 to $93.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.